CHARLES MADY

(Fonte: Lattes)
Índice h a partir de 2011
17
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2018 ×

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • article 5 Citação(ões) na Scopus
    Erythropoietin reduces collagen deposition after myocardial infarction but does not improve cardiac function
    (2018) PESSOA, Fernanda Gallinaro; MADY, Charles; FONSECA, Keila Cardoso Barbosa; OLIVEIRA-FONOFF, Adriana Morgan de; SALEMI, Vera Maria Cury; JORDAO, Mauricio Rodrigues; FERNANDES, Fabio; RAMIRES, Felix Jose Alvarez
    Myocardial remodeling includes inappropriate collagen deposition in the interstitium. Erythropoietin (EPO) may have cardioprotective effects. We aimed to assess the role of EPO on myocardial remodeling during the chronic phase. We studied 60 Wistar rats divided into the following groups: control (CT), control + EPO (CT + EPO), myocardial infarction + EPO (MI + EPO), and myocardial infarction (MI). The interstitial collagen volume fraction (ICVF) was quantified and echocardiography was performed. We quantified asymmetric dimethylarginine and glutathione by ELISA, and used real-time PCR to assess apoptosis and inflammation. Western blotting was used to evaluate inflammatory proteins and tissue inhibitors of metalloproteinases (TIMPs), and TUNEL staining was used to detect apoptosis. For matrix metalloproteinases (MMPs), we performed zymography. Parametric and nonparametric analyses were performed according to normality testing. ICVF was greater in MI groups (p < 0.001) and was attenuated by EPO (p = 0.05). The MMP-2 did not show any difference between groups. The TIMP-1 and TIMP-2 did not have difference between groups. The MI groups had worse fraction shortening (p < 0.001), without EPO protection (p = 0.666). The MI groups had increased left ventricle diastolic dimension (p < 0.001) without EPO attenuation (p = 0.79). EPO did not act on oxidative stress. Apoptosis and inflammation were not modulated by EPO. We concluded that EPO attenuated interstitial collagen accumulation, but did not protect from heart dilation or dysfunction.
  • bookPart
    Miocardites agudas
    (2018) MANGINI, Sandrigo; FERNANDES, Fábio; MADY, Charles
  • conferenceObject
    Galectin-3 levels are normal in patients with constrictive pericarditis and are associated with exercise intolerance after pericardiectomy
    (2018) FERNANDES, F.; MELLO, D. T. P.; RAMIRES, F. J. A.; SABINO, E. C.; MOREIRA, C. H. V.; BENVENUTTI, L.; HOTTA, V. T.; SAYEG, A.; DIAS, R. R.; MADY, C.
  • conferenceObject
    Effects of exercise training on cardiovascular autonomic modulation and skeletal muscle tissue in chagasic cardiopathy patients and preserved systolic function
    (2018) SARMENTO, A. S. O.; ANTUNES-CORREA, L. M.; ALVES, M. J. N. N.; BACURAU, A. V. N.; FONSECA, K. C. B.; PESSOA, F. G.; TROMBETTA, I. C.; RONDON, M. U. P. B.; RAMIRES, F. J. A.; BRASILEIRO-SANTOS, M. S.; BRUM, P. C.; MADY, C.; NEGRAO, C. E.; THOMAS, S.; IANNI, B. M.
  • conferenceObject
    Dysregulation of insulin levels in Chagas heart disease is associated with altered adipocytokine levels
    (2018) DABARIAN, A.; MADY, C.; FERREIRA, J. M. B.; IANNI, B.; HOTTA, V. T.; RAMIRES, F. J. A.; LOPES, H. F.; FERNANDES, F.
  • bookPart
    Miocardites agudas
    (2018) MANGINI, Sandrigo; FERNANDES, Fábio; MADY, Charles
  • article 57 Citação(ões) na Scopus
    Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy
    (2018) SENRA, Tiago; IANNI, Barbara M.; COSTA, Ana C. P.; MADY, Charles; MARTINELLI-FILHO, Martino; KALIL-FILHO, Roberto; ROCHITTE, Carlos E.
    BACKGROUND Myocardial fibrosis (MF) according to cardiac magnetic resonance (CMR) is a frequent finding in Chagas cardiomyopathy and has been associated with risk factors of poor outcome. OBJECTIVES The goal of this study was to determine the prognostic value of MF in predicting combined hard events or all-cause mortality. METHODS Patients with Chagas cardiomyopathy who had a previous CMR evaluation were included, and clinical follow-up was retrospectively obtained. The primary outcome was a combination of all-cause mortality, heart transplantation, antitachycardia pacing or appropriate shock from an implantable cardioverter-defibrillator, and aborted sudden cardiac death; the secondary outcome was all-cause mortality. RESULTS A total of 130 patients were included; mean age was 53.6 +/- 11.5 years, and 53.9% were female. The majority of patients reported no symptoms of heart failure or arrhythmia, but electrocardiographic and echocardiographic abnormalities were common. On CMR, left ventricular dilatation and dysfunction were frequent, and MF was found in 76.1%, with a mean mass of 15.2 +/- 16.5 g. Over a median follow-up of 5.05 years, 58 (44.6%) patients reached the combined endpoint, and 45 (34.6%) patients died. MF was associated with the primary outcome as a continuous variable (adjusted hazard ratio: 1.031; 95% CI: 1.013 to 1.049; p = 0.001) and as a categorical variable (MF >= 12.3 g) (adjusted hazard ratio: 2.107; 95% CI: 1.111 to 3.994; p = 0.022), independently from the Rassi risk score. MF expressed as a continuous variable was also associated with all-cause mortality (adjusted hazard ratio: 1.028; 95% CI: 1.005 to 1.051; p = 0.017) independently from the Rassi risk score. CONCLUSIONS MF is an independent predictor of adverse outcome in Chagas cardiomyopathy. Our data may support the use of CMR in better risk-stratifying this population and possibly guiding therapy. (c) 2018 by the American College of Cardiology Foundation.